Pulmonary and Critical Care

Pulmonary and Critical Care

For additional information on the enrolling clinical research studies listed below, or to inquire about enrollment, contact the individual listed for the study.

For general inquiries about other clinical research being conducted at OSF HealthCare locations, contact us at osf.clinicalresearch@osfhealthcare.org.

Cystic Fibrosis

  • STOP2: Standardized Treatment of Pulmonary Exacerbations II

  • Summary: This study is to evaluate the effectiveness and safety of differing durations of IV treatment, given in the hospital or at home, for a pulmonary exacerbation in adult patients with cystic fibrosis.

    Investigator: Subramanyam Chittivelu

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    ClinicalTrials.gov: NCT03525548

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

  • PTI-801-01: A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects with Cystic Fibrosis

  • Summary: Part 1 will enroll adult healthy volunteers (HV) into four treatment groups: 1) a single ascending dose (SAD) treatment group consisting of three cohorts; 2) a multiple ascending dose (MAD) treatment group consisting of three cohorts; 3) a food effect (FE) treatment group consisting of one cohort; and 4) a drug-drug interactions (DDI) treatment group consisting of one cohort. Part 2 Cohorts 1 through 3 will enroll adult subjects with cystic fibrosis (CF) currently on stable ivacaftor/lumacaftor background therapy for a minimum of three months into a MAD treatment group consisting of three cohorts. Part 2 Cohort 4 will enroll adult subjects with CF not currently receiving or have received cystic fibrosis conductance regulator (CFTR) modulator therapy within 30 days prior to Day 1.

    Investigator: Subramanyam Chittivelu

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    ClinicalTrials.gov: NCT03525548

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

  • VX17-445-102: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis Who are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

  • Summary: This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF subjects).

    Investigator: Subramanyam Chittivelu

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    ClinicalTrials.gov: NCT03525548

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

  • VX17-445-103: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)

  • Summary: This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation (F/F).

    Investigator: Subramanyam Chittivelu

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    ClinicalTrials.gov: NCT03525548

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

Interventional Pulmonary

  • Bronchoscopic Lung Biopsy Enhancement with LungVision® device

  • Summary: A study that collects data from lung biopsy procedures in order to optimize the performance of the LungVision® device

    Investigator: Patrick Whitten

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

  • The PERCEPTA Registry

  • Summary: This is a prospective registry to evaluate Percepta bronchial genomic classifier patient data

    Investigator: Patrick Whitten

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org

  • IBV Valve System (Humanitarian Use Device)

  • Summary: For the control of prolonged air leaks of the lung, or significant air leaks that are likely to become prolonged following lobectomy, segmentectomy, or lung volume reduction surgery

    Investigator: Patrick Whitten

    Location: OSF HealthCare Saint Francis Medical Center, Peoria, Illinois

    Contact: Ashley Scott, (309) 624-2409, ashley.scott@osfhealthcare.org